NCT05860582View on ClinicalTrials.gov

A Study of [14C]GB491 in Male Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

November 14, 2022

Study Completion Date

November 14, 2022

Conditions
Breast CancerNonsmall Cell Lung Cancer
Interventions
DRUG

[14C]GB491

A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.

Trial Locations (1)

100070

Beijing GoBroad Boren Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Genor Biopharma Co., Ltd.

INDUSTRY